BRAF V600E 突变在结直肠癌（CRC）中是一个重要的生物标志物，约占所有结直肠癌病例的 10%。这一突变通常与肿瘤的侵袭性、预后不良以及对常规化疗 ...

New York, USA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- BRAF Inhibitors Market to Register Incremental Growth During the Study Period (2020–2034) | DelveInsight The BRAF Inhibitors market is expected ...

Recombinant human TSH (rhTSH) was developed to provide TSH stimulation without the requirement for THST withdrawal and the ...

(MENAFN- GlobeNewsWire - Nasdaq) The BRAF Inhibitors market is expected to grow significantly in the coming years. This is due to the increasing number of patients being diagnosed with cancer ...

New York, USA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- BRAF Inhibitors Market to Register Incremental Growth During the Study Period (2020–2034) | DelveInsight The BRAF Inhibitors market is expected to grow ...

The three-drug regimen – based on Array BioPharma/Pierre Fabre’s BRAF inhibitor Braftovi (encorafenib) and MEK inhibitor Mektovi (binimetinib) along with Eli Lilly’s EGFR-targeted antibody E ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of ...

In patients with metastatic colorectal cancer harboring a BRAF V600E mutation, the combo not only staved off disease progression but it also significantly extended patients’ lives compared with ...